Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| 11.74 | |
| 11.49 | |
| - | |
| 11.83 | |
| 11.1 | |
| 6.065-17.019 | |
| 660 M | |
| 58 535 K | |
| 2 594 K | |
| -1.42 | |
| 0.682 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Retail investor interest in short squeeze stocks has grown considerably since the “meme stock” phenomenon of 2021. However, a stock doesn’t need to gain the “meme king” popularity of a GameS...
Healthcare is a basic human need that can withstand economic downturns. Indeed, this important endeavor receives a huge amount of funds in developed countries globally and the West in particular. Roug...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
